{
  "url": "https://openlegislation.uk/eu-regulation-2009-761/annex-III/division-1/division-1.6/division-1.6.1/division-1.6.1.4",
  "json_url": "https://openlegislation.uk/eu-regulation-2009-761/annex-III/division-1/division-1.6/division-1.6.1/division-1.6.1.4.json",
  "legislation": "eur/2009/761",
  "legislation_title": "Commission Regulation (EC) No 761/2009 of 23 July 2009 amending, for the purpose of its adaptation to technical progress, Regulation (EC) No 440/2008 laying down test methods pursuant to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) (Text with EEA relevance)",
  "legislation_url": "https://openlegislation.uk/eu-regulation-2009-761",
  "path": "annex/III/division/1/division/1.6/division/1.6.1/division/1.6.1.4",
  "kind": "division",
  "number": "1.6.1.4",
  "heading": "Cell Viability Measurements",
  "text": "The most important element of the test procedure is that viability measurements are not performed immediately after the exposure to the test substances, but after a sufficiently long post-treatment incubation period of the rinsed tissues in fresh medium. This period allows both for recovery from weakly irritant effects and for appearance of clear cytotoxic effects. During the test optimisation phase (9, 10, 11, 12, 13), a 42 hours post-treatment incubation period proved to be optimal and was therefore used in the validation of the reference test methods.\nThe MTT conversion assay is a quantitative validated method which should be used to measure cell viability. It is compatible with use in a three-dimensional tissue construct. The skin sample is placed in MTT solution of appropriate concentration (e.g. 0,3-1 mg/mL) for 3 hours. The precipitated blue formazan product is then extracted from the tissue using a solvent (e.g. isopropanol, acidic isopropanol), and the concentration of formazan is measured by determining the OD at 570 nm using a bandpass of maximum ±30 nm.\nOptical properties of the test substance or its chemical action on the MTT may interfere with the assay leading to a false estimate of viability (because the test substance may prevent or reverse the colour generation as well as cause it). This may occur when a specific test substance is not completely removed from the skin by rinsing or when it penetrates the epidermis. If the test substance acts directly on the MTT, is naturally coloured, or becomes coloured during tissue treatment, additional controls should be used to detect and correct for test substance interference with the viability measurement technique. For detailed description of how to test direct MTT reduction, please consult the test method protocol for the validated reference methods (21, 22, 23). Non-specific colour (NSC) due to these interferences should not exceed 30 % of NC (for corrections). If NSC > 30 %, the test substance is considered as incompatible with the test.",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/2009/761/annex/III/division/1/division/1.6/division/1.6.1/division/1.6.1.4",
    "retrieved_at": "2026-11-01T14:51:19.625001+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}